Bidders Hike Offers For India’s Fortis As Acquisition War Intensifies
Leading Malaysian healthcare operator IHH and two Indian tycoons have sweetened their offers for cash-strapped Fortis Healthcare as the race for India’s second-largest hospital chain heats up.
You may also be interested in...
Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.
Daiichi Sankyo has demanded that an Indian court block a mega-deal to sell Indian hospital chain Fortis to a local healthcare provider until the hospital chain’s founders, Malvinder Singh and Shivinder Singh, pay a $550m international arbitration award to the Japanese drugmaker.
Shares of Indian hospital chain Fortis Healthcare have risen some 16% in the past month, fuelled by investor hopes of a takeover battle for the financially troubled company. US hedge fund Elliott Management is now said to have entered the fray and be buying up stock.